Sections
| Title | Starting Page | Number of Pages |
|---|
| COVER | 1 | 3 |
| PLUNKETT S BIOTECH &GENETICS INDUSTRY TRENDS &STATISTICS 2014 | 4 | 3 |
| CONTENTS | 7 | 2 |
| Chapter 1 MAJOR TRENDS AFFECTING THE BIOTECH &GENETICS INDUSTRY | 9 | 44 |
| 1) The State of the Biotechnology Industry Today | 10 | 6 |
| 2) A Short History of Biotechnology | 16 | 1 |
| 3) Ethanol Production Soared, But U.S. Federal Subsidy Expires | 17 | 4 |
| 4) Major Drug Companies Acquire or Partner with Smaller Biotech Firms | 21 | 1 |
| 5) From India to Singapore to China, Nations Compete Fiercely in Biotech Development | 22 | 2 |
| 6) Clinical Trials and Medical Records Processing Conducted Abroad Spark Concerns | 24 | 1 |
| 7) Gene Therapies and Patients Genetic Profiles Promise a Personalized Approach to Medicine | 25 | 2 |
| 8) Vaccines and Viruses in Drug Delivery | 27 | 1 |
| 9) Few New Blockbusters: Major Drug Patents Expire While Generic Sales Growth Continues/Research Focus Shifts | 28 | 3 |
| 10) Biotech and Orphan Drugs Pick Up the Slack as Blockbuster Mainstream Drugs Age | 31 | 2 |
| 11) Biosimilars (Generic Biotech Drugs) Receive FDA Guidelines for Accelerated Approval/Competition Will Be Fierce | 33 | 1 |
| 12) Breakthrough New Drug Delivery Systems Evolve | 34 | 1 |
| 13) Stem Cells Multiple Sources Stem from New Technologies | 35 | 2 |
| 14) Government Support for New Stem Cell Research Evolves | 37 | 1 |
| 15) Stem Cells Therapeutic Cloning Techniques Advance | 38 | 2 |
| 16) Stem Cells A New Era of Regenerative Medicine TakesShape | 40 | 2 |
| 17) Nanotechnology Converges with Biotech | 42 | 1 |
| 18) Agricultural Biotechnology Scores Breakthroughs but Causes Controversy/Selective Breeding Offers a Compromise | 43 | 4 |
| 19) Focus on Vaccines | 47 | 1 |
| 20) Technology Discussion Genomics and Personal Gene Profiles | 48 | 1 |
| 21) Technology Discussion Proteomics | 49 | 1 |
| 22) Technology Discussion Microarrays | 49 | 1 |
| 23) Technology Discussion DNA Chips | 50 | 1 |
| 24) Technology Discussion SNPs ( Snips ) | 51 | 1 |
| 25) Technology Discussion Combinatorial Chemistry | 51 | 1 |
| 26) Technology Discussion Synthetic Biology | 51 | 1 |
| 27) Technology Discussion Recombinant DNA | 52 | 1 |
| 28) Technology Discussion Polymerase Chain Reaction (PCR) | 52 | 1 |
| Chapter 2 BIOTECH &GENETICS INDUSTRY STATISTICS | 53 | 20 |
| Biotech Industry Overview | 54 | 1 |
| The U.S. Drug Discovery &Approval Process | 55 | 1 |
| U.S. FDA New Drug (NDA) and Biologic (BLA) Approvals, 2012 | 56 | 1 |
| U.S. Pharmaceutical R&D Spending Versus the Number of New Molecular Entity (NME) Approvals: 1993-2012 | 57 | 1 |
| Employment in Life &Physical Science Occupations, U.S.: May 2012 | 58 | 1 |
| Federal R&D &R&D Plant Funding for General Science &Basic Research, U.S.: Fiscal Years 2011-2013 | 59 | 1 |
| U.S. Exports &Imports of Pharmaceutical Products: 2007-1st Quarter 2013 | 60 | 1 |
| U.S. Prescription Drug Expenditures, Aggregate &Per Capita Amounts, Percent Distribution: 2006-2021 | 61 | 2 |
| U.S. Prescription Drug Expenditures: 1970-2021 | 63 | 2 |
| Total U.S. Biotechnology Patents Granted per Year by Patent Class: 1977-2012 | 65 | 1 |
| Research Funding for Biological Sciences, U.S. National Science Foundation: Fiscal Years 2012-2014 | 66 | 1 |
| Global Area of Biotech Crops by Country: 2012 | 67 | 1 |
| Domestic &Foreign Pharmaceutical Sales, PhRMA Member Companies: 1975-2012 | 68 | 1 |
| Sales By Geographic Area, PhRMA Member Companies: 2011 | 69 | 1 |
| Domestic U.S. Biopharmaceutical R&D &R&D Abroad, PhRMA Member Companies: 1975-2012 | 70 | 1 |
| Domestic U.S. Biopharmaceutical R&D &R&D Abroad Breakdown, PhRMA Member Companies: 2011 | 71 | 2 |
